High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases

Moiseyenko, Vladimir; Проценко, Светлана; Brezhnev, Nikita V.; Gershveld, Eduard D.; Hudyakova, Marina A.; Lobeiko, Oksana S; Gergova, Madina M.; Krzhivitskiy, Pavel; Semionov, Igor I.; Matsko, Dmitry E.; Iyevleva, Aglaya G.; Sokolenko, Anna P.; Sherina, Natalia; Kuligina, Ekatherina Sh.; Suspitsin, Evgeny N.; Togo, Alexandr V.; Imyanitov, Evgeny N.

doi:10.1016/j.cancergencyto.2009.10.003

Cited by 18 publications

(17 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While designing this study, we referred to our earlier experience of administering single-agent cisplatin at 100 mg/m 2 or single-agent mitomycin C at 10 mg/m 2 to BRCA1 germline mutation carriers. 10,25,26 We assumed that the use of dose-intensive combination of these drugs could increase the chances of obtaining pCR and prevent the selection of resistant clones in BRCA1-associated tumors, thus providing an opportunity for a cure at least to some patients. Overall, the toxicity profile of the combination of cisplatin (100 mg/m 2 ) and mitomycin C (10 mg/m 2 ), given every 4 weeks, looked acceptable (Table 3).…”

Section: Discussionmentioning

confidence: 99%

Atl

Gorodnova

Kotiv

Ivantsov

et al. 2018

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

ObjectivesCisplatin and mitomycin C exert high activity towards BRCA1-deficient cells. This study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1-associated ovarian cancer (OC).MethodsTwelve OC patients, who could not be treated by primary debulking surgery owing to extensive tumor spread, were given neoadjuvant cisplatin (100 mg/m2) and mitomycin C (10 mg/m2) every 4 weeks for 3 (n = 9), 2 (n = 2), or 4 (n = 1) cycles.ResultsThe decrease of tumor burden and complete surgical cytoreduction were achieved in all patients. Pathologic complete response, defined as the absence of tumor cells in surgically removed tissues, was observed in 2 (17%) of 12 cases. Retrospective analysis of 62 OC in BRCA1 mutation carriers subjected to conventional neoadjuvant chemotherapy schemes revealed 36 objective tumor responses (58%) and 37 instances (60%) of complete cytoreductive surgery; however, none of these patients demonstrated pathologic complete response.ConclusionsThe combination of cisplatin plus mitomycin C showed promising results in BRCA1-driven OC and therefore deserves further clinical evaluation.

show abstract

Section: Discussionmentioning

confidence: 99%

Atl

Gorodnova

Kotiv

Ivantsov

et al. 2018

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Response rates in BRCA2 mutation carriers are not yet defined, and this study has not yet been published. To date, the data on the efficacy of singleagent cisplatin in BRCA mutation-associated breast cancers is limited to 16 BRCA1 carriers [9,[28][29][30]. Therefore, we need specifically designed prospective studies assessing the cisplatin efficacy in distinct categories of BRCA carriers before suggesting that we should routinely incorporate platinum agents into neo/adjuvant therapy in BRCA1 carriers.…”

Section: Dna-damaging Agentsmentioning

confidence: 95%

Systemic therapy options in BRCA mutation-associated breast cancer

Bayraktar

Glück

2012

Breast Cancer Res Treat

View full text Add to dashboard Cite

“…Russian scientists were the first to provide independent confirmation of the results of Byrski et al . [42]. Cisplatin is now commonly used for the therapy of BRCA1 -associated tumors in several Russian clinics.…”

Section: Medical Aspects Of Hereditary Bc and Oc In Russiamentioning

confidence: 99%

Hereditary Breast-Ovarian Cancer Syndrome in Russia

et al. 2010

View full text Add to dashboard Cite

Hereditary breast-ovarian cancer syndrome contributes to as much as 5–7% of breast cancer (BC) and 10–15% of ovarian cancer (OC) incidence. Mutations in the “canonical” genesBRCA1andBRCA2occur in 20–30% of affected pedigrees. In addition toBRCA1andBRCA2 mutations, germ-line lesions in theCHEK2,NBS1, andPALB2genes also contribute to familial BC clustering. The epidemiology of hereditary breast-ovarian cancer in Russia has some specific features. The impact of the “founder” effect is surprisingly remarkable: a single mutation,BRCA15382insC, accounts for the vast majority ofBRCA1defects across the country. In addition, there are two other recurrentBRCA1alleles:BRCA14153delA andBRCA1185delAG. BesidesBRCA1, in Russia breast cancer is often caused by germ-line alterations in theCHEK2andNBS1genes. In contrast toBRCA1andBRCA2, theCHEK2andNBS1heterozygosity does not significantly increase the OC risk. Several Russian breast cancer clinics recently started to investigate the efficacy of cisplatin in the therapy ofBRCA1-related cancers; initial results show a unique sensitivity ofBRCA1-associated tumours to this compound.

show abstract

High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases

Cited by 18 publications

References 10 publications

Atl

Atl

Systemic therapy options in BRCA mutation-associated breast cancer

Hereditary Breast-Ovarian Cancer Syndrome in Russia

Contact Info

Product

Resources

About